Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Immunogenicity of a 2-dose priming and booster vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine

Research output: Contribution to journalJournal articleResearchpeer-review

  1. LISTERIA MENINGITIS IN DANISH CHILDREN 2000-2017: A Rare Event Even in a Country With High Rates of Invasive Listeriosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Pediatric Candidemia Epidemiology and Morbidities: A Nationwide Cohort

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Streptococcal Infections and Exacerbations in PANDAS: A Systematic Review and Meta-analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Hepatitis B virus upregulates host microRNAs that target apoptosis-regulatory genes in an in vitro cell model

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Identification of valid reference genes for microRNA expression studies in a hepatitis B virus replicating liver cell line

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Forskning under medicinstudiet (kan) hæmmes af fremdriftsreformen

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Defective Natural Killer cell antiviral capacity in paediatric HBV infection

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Sven Arne Silfverdal
  • Birthe Høgh
  • Marianne Riise Bergsaker
  • Helena Skerlikova
  • Patricia Lommel
  • Dorota Borys
  • Lode Schuerman
View graph of relations
BACKGROUND: The immunogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) was determined following a simplified 2-dose priming and the more commonly employed 3-dose priming both followed by a booster dose. METHODS: A total of 351 healthy subjects were primed with PHiD-CV at either 3 and 5 or 3, 4 and 5 months of age followed in all subjects by a booster dose at 11 to 12 months of age. Serotype-specific pneumococcal responses were measured by 22F-inhibition ELISA and opsonophagocytic assays 1 month following primary and booster vaccinations. RESULTS: Depending on the serotype, the percentages of subjects reaching the ELISA antibody threshold of 0.2 microg/mL were 92.8% to 98.0% following 2 primary doses and 96.1% to 100% following 3 primary doses except for serotype 6B (55.7% and 63.1%, respectively) and serotype 23F (69.3% and 77.6%, respectively). Opsonophagocytic activity (OPA) could be measured in 74.4% to 100% and 88.9% to 100% of the subjects after the 2-dose or 3-dose priming, respectively, except for serotype 1 (60.8% and 62.9%, respectively). In both groups, robust increases in ELISA antibodies and OPA titers were observed for all serotypes after the booster dose. Higher postprimary and postbooster ELISA antibody levels and OPA titers were observed for most serotypes following the 3+1 schedule. CONCLUSION: PHiD-CV was immunogenic in both schedules, but further effectiveness data are needed to fully understand the public health benefit to be expected from these schedules in terms of prevention against invasive and mucosal infections.
Original languageEnglish
JournalThe Pediatric infectious disease journal
Volume28
Issue number10
Pages (from-to)e276-82
DOIs
Publication statusPublished - 2009

    Research areas

  • Antibodies, Bacterial, Bacterial Proteins, Carrier Proteins, Enzyme-Linked Immunosorbent Assay, Female, Haemophilus Vaccines, Humans, Immunization, Secondary, Immunoglobulin D, Infant, Lipoproteins, Male, Opsonin Proteins, Phagocytosis, Pneumococcal Vaccines, Vaccination, Vaccines, Conjugate

ID: 32577438